NCT06956001 2026-02-12
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
Allist Pharmaceuticals, Inc.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Rutgers, The State University of New Jersey
Klus Pharma Inc.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shanghai Hengrui Pharmaceutical Co., Ltd.